Trials & R&D · first seen 1h ago, updated 1h ago

Novo is betting on its next chapter as Eli Lilly gains more ground in GLP-1s

1 outlet GLP-1 & obesity drugs Eli Lilly

As Novo works to turn itself around, some analysts say Lilly has advantages that could help it maintain its position at the top of the obesity drug market.

Summary from CNBC Health & Science.

Coverage 1 article · 1 outlet

CNBC Health & Science 1h ago
Novo is betting on its next chapter as Eli Lilly gains more ground in GLP-1s